Clinical trials in Hradec Kralove – page 4

191 clinical trials in Hradec Kralove, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in CzechiaKlinickeTesty.cz

Hradec Kralove at a glance

191

clinical trials

Paediatric trials0
Research sites0

Quick filters

191 trials in Hradec Kralove

Open in trial search

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Guselkumab
Sponsor:Janssen Cilag International

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Neuroendocrine carcinoma

Recruiting

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Chronic lymphocytic leukaemia recurrent+1

Recruiting

A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment

Registered drugNo placebo

A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:AstraZeneca AB

Contact Research Centre

B-cell small lymphocytic lymphoma

Recruiting

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:BeOne Medicines I GmbH

Contact Research Centre

Acute lymphocytic leukaemia

Recruiting

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Asparaginase
Sponsor:Amgen Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:AZD5335
Sponsor:AstraZeneca AB

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Hradec Kralove

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative research focusing on inflammatory bowel diseases, including studies evaluating new therapies for both ulcerative colitis and Crohn's disease. Clinical trials are investigating advanced treatments like OD-07656 and TAK-279 for managing moderate to severe cases.

Ulcerative Colitis Treatment
Crohn's Disease Management
Clostridioides difficile Studies

Additional research explores antibiotic optimization and novel therapeutic combinations.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for metastatic prostate cancer and advanced gastric cancers. Research focuses on innovative therapies combining targeted treatments with immunotherapy approaches.

Prostate Cancer Therapeutics
Gastric Cancer Treatment
Melanoma Interventions

Investigations include novel drug combinations and immunotherapy strategies.

03 Neurological Conditions

Advanced research in multiple sclerosis and Parkinson's disease, evaluating new therapeutic approaches and comparing treatment efficacies. Studies include assessments of innovative medications and comparative analyses.

Multiple Sclerosis Treatments
Parkinson's Disease Therapy
Stroke Management

Focus on both disease-modifying treatments and symptom management.

Back to Czechia All countries